Physician profile
Deepa Koshti
NPI 1093163651
$2,146.80
in general payments reported to CMS, 2019-2025
24 companies · $582 in 2025
The $582 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $96.34 · 2022: $400 · 2023: $486 · 2024: $582 · 2025: $582.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,650.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,650.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $396.76 | 2022-2025 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $241.64 | 2022-2025 | |
| Travere Therapeutics, INC. | $195.86 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $152.41 | 2021-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $145.78 | 2024-2025 | |
| Calliditas Therapeutics US INC. | $135.23 | 2023-2025 | Tarpeyo |
| Opko Pharmaceuticals, LLC | $120.42 | 2023-2025 | Rayaldee |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.55 | 2023-2025 | Jardiance |
| Alexion Pharmaceuticals, INC. | $109.59 | 2023-2025 | Ultomiris |
| Takeda Pharmaceuticals U.S.A., INC. | $66.55 | 2022 | |
| Lilly USA, LLC | $59.61 | 2024-2025 | Jardiance |
| Amgen INC. | $58.59 | 2021-2024 | Krystexxa |
| Abbvie INC. | $55.36 | 2023 | |
| Ardelyx, INC. | $43.82 | 2024-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $42.39 | 2022-2024 | Prevymis |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $36.45 | 2023 | Veltassa |
| Glaxosmithkline, LLC. | $34.09 | 2023 | Benlysta |
| Genzyme Corporation | $27.11 | 2022 | |
| Kyowa Kirin, INC. | $22.98 | 2025 | |
| Pfizer INC. | $22.26 | 2023 | |
| Mallinckrodt Hospital Products INC. | $21.16 | 2024 | Terlivaz |
| United Therapeutics Corporation | $18.02 | 2023 | Tyvaso |
| Paratek Pharmaceuticals, INC. | $17.14 | 2022 | |
| Abbott Laboratories | $12.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepa Koshti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.